Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Up 16.4% – Should You Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares traded up 16.4% during trading on Thursday . The company traded as high as $13.37 and last traded at $13.10. Approximately 1,369,571 shares were traded during mid-day trading, an increase of 4% from the average session volume of 1,317,666 shares. The stock had previously closed at $11.25.

Analyst Ratings Changes

A number of research firms recently weighed in on BAYRY. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Finally, Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Up 16.4%

The company has a market capitalization of $51.48 billion, a P/E ratio of -20.47, a price-to-earnings-growth ratio of 3.51 and a beta of 0.59. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The stock’s fifty day moving average is $10.92 and its 200 day moving average is $11.47.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Research analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.